A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship

Erlangga Yusuf; Markus Zeitlinger; Sylvain Meylan

doi:10.1093/jac/dkac413

A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship

Erlangga Yusuf, Markus Zeitlinger, Sylvain Meylan

Medical Microbiology & Infectious Diseases

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

The interpretation of 'susceptible (S)' or 'resistant (R)' results of antimicrobial susceptibility testing is easily understood, but the interpretation of the 'intermediate (I)' category can be confusing. This review critically discusses how this categorization (clinical breakpoints) comes into being with the emphasis on the use of pharmacokinetics and pharmacodynamic data. It discusses the differences between the 'I' according to the CLSI and the EUCAST. This review also discusses the recent EUCAST change of the 'I' definition, and the impact of this change from laboratory and clinical points of view.

Original language	English
Pages (from-to)	338-345
Number of pages	8
Journal	The Journal of antimicrobial chemotherapy
Volume	78
Issue number	2
DOIs	https://doi.org/10.1093/jac/dkac413
Publication status	Published - 1 Feb 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkac413

Cite this

@article{f3c0859a8dd04e2c8312d1c04968196c,

title = "A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship",

abstract = "The interpretation of 'susceptible (S)' or 'resistant (R)' results of antimicrobial susceptibility testing is easily understood, but the interpretation of the 'intermediate (I)' category can be confusing. This review critically discusses how this categorization (clinical breakpoints) comes into being with the emphasis on the use of pharmacokinetics and pharmacodynamic data. It discusses the differences between the 'I' according to the CLSI and the EUCAST. This review also discusses the recent EUCAST change of the 'I' definition, and the impact of this change from laboratory and clinical points of view.",

author = "Erlangga Yusuf and Markus Zeitlinger and Sylvain Meylan",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2023",

month = feb,

day = "1",

doi = "10.1093/jac/dkac413",

language = "English",

volume = "78",

pages = "338--345",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "2",

}

A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship. / Yusuf, Erlangga; Zeitlinger, Markus; Meylan, Sylvain.
In: The Journal of antimicrobial chemotherapy, Vol. 78, No. 2, 01.02.2023, p. 338-345.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - A narrative review of the intermediate category of the antimicrobial susceptibility test

T2 - relation with dosing and possible impact on antimicrobial stewardship

AU - Yusuf, Erlangga

AU - Zeitlinger, Markus

AU - Meylan, Sylvain

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - The interpretation of 'susceptible (S)' or 'resistant (R)' results of antimicrobial susceptibility testing is easily understood, but the interpretation of the 'intermediate (I)' category can be confusing. This review critically discusses how this categorization (clinical breakpoints) comes into being with the emphasis on the use of pharmacokinetics and pharmacodynamic data. It discusses the differences between the 'I' according to the CLSI and the EUCAST. This review also discusses the recent EUCAST change of the 'I' definition, and the impact of this change from laboratory and clinical points of view.

AB - The interpretation of 'susceptible (S)' or 'resistant (R)' results of antimicrobial susceptibility testing is easily understood, but the interpretation of the 'intermediate (I)' category can be confusing. This review critically discusses how this categorization (clinical breakpoints) comes into being with the emphasis on the use of pharmacokinetics and pharmacodynamic data. It discusses the differences between the 'I' according to the CLSI and the EUCAST. This review also discusses the recent EUCAST change of the 'I' definition, and the impact of this change from laboratory and clinical points of view.

UR - http://www.scopus.com/inward/record.url?scp=85147234406&partnerID=8YFLogxK

U2 - 10.1093/jac/dkac413

DO - 10.1093/jac/dkac413

M3 - Review article

C2 - 36583270

AN - SCOPUS:85147234406

SN - 0305-7453

VL - 78

SP - 338

EP - 345

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 2

ER -

A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this